Clinical trials face soaring costs, long timelines, and high failure rates, but generative AI offers a breakthrough. The WEF and ZS white paper highlights how Gen AI can transform five key areas: trial design, feasibility and site selection, recruitment and retention, data analysis, and regulatory submission. Benefits include faster recruitment, fewer amendments, automated submissions, and decentralized trials. Case studies from Moderna, Amgen, and Mass General show AI’s potential to cut costs and boost accuracy. Barriers remain—fragmented data, skill gaps, regulatory uncertainty, and trust—but coordinated action could unlock $1B+ in savings for top pharma firms while accelerating patient access to therapies.

Join for free to read